Study of Dasatinib in Patients with CML

Article

This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib.

Study Type: Interventional

Age/Sex Requirements: 16 years+ (None)

Sponsor: MD Anderson Cancer Center

Purpose: This clinical trial will assess the safety of dasatinib and whether this drug can help control CML in chronic phase. The study is split into two arms, with patients starting on a dosage of either 100 mg once daily or 50 mg twice daily of dasatinib. The primary outcome measure will be the time to first molecular response prior to 12 months.

Click here to access this third-party website.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
A panel of 5 experts on iron deficiency anemia
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Phase 2 Data Shows KP1077 Meaningfully Improves Idiopathic Hypersomnia Symptoms
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
© 2024 MJH Life Sciences

All rights reserved.